BioCentury | May 10, 2010
Clinical News

IDEA-067: Phase III started

...27, 2006). Celtic Pharmaceutical Holdings L.P. , Hamilton, Bermuda Idea AG , Munich, Germany Product: IDEA-067...
BioCentury | Jun 8, 2009
Finance

Ebb & Flow

Triple threat For those keeping score at home, Carl Icahn's right hand man in biotech, Alexander Denner, has joined the boards of three biotechnology companies in the last month: Biogen Idec Inc. (NASDAQ:BIIB), Amylin Pharmaceuticals...
BioCentury | Mar 30, 2009
Clinical News

TDT-067: Phase II data

...AG , Munich, Germany Product: TDT-067 (formerly IDEA-067 ) Business: Infectious Molecular target: NA Description: Topical terbinafine...
BioCentury | Mar 27, 2009
Clinical News

Celtic's TDT-067 meets Phase II endpoint

...II trial to treat onychomycosis, with a 90% cure rate. The open-label study of the topical terbinafine...
BioCentury | Oct 22, 2007
Clinical News

Terbinafine: Phase II started

...Celtic began a Phase II trial of topical terbinafine. The company has exclusive rights to IDEA's Transfersome...
BioCentury | Feb 27, 2006
Strategy

The sum greater than the whole

...inflammation and IDEA-068/072 is in Phase I to treat dermatitis and psoriasis. Preclinical projects include IDEA-067...
BioCentury | Feb 27, 2006
Company News

Idea, Celtic Pharma deal

...and inflammation; IDEA-068/072, which is in Phase I testing to treat dermatitis and psoriasis; and IDEA-067...
BioCentury | Feb 24, 2006
Company News

Celtic acquires Idea's dermatology products

...and inflammation; IDEA-068/072, which is in Phase I testing to treat dermatitis and psoriasis; and IDEA-067...
Items per page:
1 - 8 of 8